Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy

Shahad K. Alsaiari; Somayah S. Qutub; Shichao Sun; Walaa Baslyman; Mansour M. Aldehaiman; Mram Z. Alyami; Abdulaziz Almalik; Rabih Halwani; Jasmeen Merzaban; Zhengwei Mao; Shahad K. Alsaiari

doi:10.1126/sciadv.abe7174

Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy

Shahad K. Alsaiari, Somayah S. Qutub, Shichao Sun, Walaa Baslyman, Mansour M. Aldehaiman, Mram Z. Alyami, Abdulaziz Almalik, Rabih Halwani, Jasmeen Merzaban, Zhengwei Mao, Shahad K. Alsaiari

Research output: Contribution to journal › Article › peer-review

62 Scopus citations

Abstract

The major impediments to the implementation of cancer immunotherapies are the sustained immune effect and the targeted delivery of these therapeutics, as they have life-threatening adverse effects. In this work, biomimetic metal-organic frameworks [zeolitic imidazolate frameworks (ZIFs)] are used for the controlled delivery of nivolumab (NV), a monoclonal antibody checkpoint inhibitor that was U.S. Food and Drug Administration–approved back in 2014. The sustained release behavior of NV-ZIF has shown a higher efficacy than the naked NV to activate T cells in hematological malignancies. The system was further modified by coating NV-ZIF with cancer cell membrane to enable tumor-specific targeted delivery while treating solid tumors. We envisage that such a biocompatible and biodegradable immunotherapeutic delivery system may promote the development and the translation of hybrid superstructures into smart and personalized delivery platforms.

Original language	English (US)
Pages (from-to)	eabe7174
Journal	Science advances
Volume	7
Issue number	4
DOIs	https://doi.org/10.1126/sciadv.abe7174
State	Published - Jan 22 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1126/sciadv.abe7174

https://repository.kaust.edu.sa/bitstream/10754/667120/1/eabe7174.full%20%281%29.pdf

Cite this

@article{12277eecbe0b426987f60cc958d87288,

title = "Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy",

abstract = "The major impediments to the implementation of cancer immunotherapies are the sustained immune effect and the targeted delivery of these therapeutics, as they have life-threatening adverse effects. In this work, biomimetic metal-organic frameworks [zeolitic imidazolate frameworks (ZIFs)] are used for the controlled delivery of nivolumab (NV), a monoclonal antibody checkpoint inhibitor that was U.S. Food and Drug Administration–approved back in 2014. The sustained release behavior of NV-ZIF has shown a higher efficacy than the naked NV to activate T cells in hematological malignancies. The system was further modified by coating NV-ZIF with cancer cell membrane to enable tumor-specific targeted delivery while treating solid tumors. We envisage that such a biocompatible and biodegradable immunotherapeutic delivery system may promote the development and the translation of hybrid superstructures into smart and personalized delivery platforms.",

author = "Alsaiari, {Shahad K.} and Qutub, {Somayah S.} and Shichao Sun and Walaa Baslyman and Aldehaiman, {Mansour M.} and Alyami, {Mram Z.} and Abdulaziz Almalik and Rabih Halwani and Jasmeen Merzaban and Zhengwei Mao and Alsaiari, {Shahad K.}",

note = "KAUST Repository Item: Exported on 2021-02-01 Acknowledgements: We thank R. Langer, Institute Professor, MIT, for feedback and comments. We acknowledge H. Alrabiah, Associate Professor at the Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University and H. I. Aljohar, Assistant Professor at the Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University for providing nivolumab.",

year = "2021",

month = jan,

day = "22",

doi = "10.1126/sciadv.abe7174",

language = "English (US)",

volume = "7",

pages = "eabe7174",

journal = "Science advances",

issn = "2375-2548",

publisher = "American Association for the Advancement of Science",

number = "4",

}

TY - JOUR

T1 - Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy

AU - Alsaiari, Shahad K.

AU - Qutub, Somayah S.

AU - Sun, Shichao

AU - Baslyman, Walaa

AU - Aldehaiman, Mansour M.

AU - Alyami, Mram Z.

AU - Almalik, Abdulaziz

AU - Halwani, Rabih

AU - Merzaban, Jasmeen

AU - Mao, Zhengwei

AU - Alsaiari, Shahad K.

N1 - KAUST Repository Item: Exported on 2021-02-01 Acknowledgements: We thank R. Langer, Institute Professor, MIT, for feedback and comments. We acknowledge H. Alrabiah, Associate Professor at the Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University and H. I. Aljohar, Assistant Professor at the Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University for providing nivolumab.

PY - 2021/1/22

Y1 - 2021/1/22

N2 - The major impediments to the implementation of cancer immunotherapies are the sustained immune effect and the targeted delivery of these therapeutics, as they have life-threatening adverse effects. In this work, biomimetic metal-organic frameworks [zeolitic imidazolate frameworks (ZIFs)] are used for the controlled delivery of nivolumab (NV), a monoclonal antibody checkpoint inhibitor that was U.S. Food and Drug Administration–approved back in 2014. The sustained release behavior of NV-ZIF has shown a higher efficacy than the naked NV to activate T cells in hematological malignancies. The system was further modified by coating NV-ZIF with cancer cell membrane to enable tumor-specific targeted delivery while treating solid tumors. We envisage that such a biocompatible and biodegradable immunotherapeutic delivery system may promote the development and the translation of hybrid superstructures into smart and personalized delivery platforms.

AB - The major impediments to the implementation of cancer immunotherapies are the sustained immune effect and the targeted delivery of these therapeutics, as they have life-threatening adverse effects. In this work, biomimetic metal-organic frameworks [zeolitic imidazolate frameworks (ZIFs)] are used for the controlled delivery of nivolumab (NV), a monoclonal antibody checkpoint inhibitor that was U.S. Food and Drug Administration–approved back in 2014. The sustained release behavior of NV-ZIF has shown a higher efficacy than the naked NV to activate T cells in hematological malignancies. The system was further modified by coating NV-ZIF with cancer cell membrane to enable tumor-specific targeted delivery while treating solid tumors. We envisage that such a biocompatible and biodegradable immunotherapeutic delivery system may promote the development and the translation of hybrid superstructures into smart and personalized delivery platforms.

UR - http://hdl.handle.net/10754/667120

UR - https://advances.sciencemag.org/lookup/doi/10.1126/sciadv.abe7174

U2 - 10.1126/sciadv.abe7174

DO - 10.1126/sciadv.abe7174

M3 - Article

C2 - 33523955

SN - 2375-2548

VL - 7

SP - eabe7174

JO - Science advances

JF - Science advances

IS - 4

ER -

Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this